

1 John Shaeffer (SBN 138331)  
jshaeffer@foxrothschild.com  
2 Lena N. Bacani (SBN 213556)  
lbacani@foxrothschild.com  
3 Jeffrey Grant (SBN 218974)  
jgrant@foxrothschild.com  
4 **FOX ROTHSCHILD LLP**  
1800 Century Park East, Suite 300  
5 Los Angeles, CA 90067-1506  
Telephone: 310-598-4150  
6 Facsimile: 310-556-9828

7 Counsel for Plaintiff,  
DRG-INTERNATIONAL, INC.  
8

9 UNITED STATES DISTRICT COURT  
10 CENTRAL DISTRICT OF CALIFORNIA  
11

12 DRG-INTERNATIONAL, INC.,  
13

14 Plaintiff,  
15

16 v.  
17

18 BACHEM AMERICAS, INC. and  
19 PENINSULA LABORATORIES  
20 INTERNATIONAL, INC.,  
21

22 Defendants.  
23  
24  
25  
26  
27  
28

Case No.: \_\_\_\_\_

Hon. Judge \_\_\_\_\_

**COMPLAINT FOR PATENT  
INFRINGEMENT**

**JURY TRIAL DEMANDED**

Complaint filed: 9/16/15

COMPLAINT OF DRG-INTERNATIONAL, INC.

1 Plaintiff DRG INTERNATIONAL, INC. seeks relief against Defendants  
2 BACHEM AMERICAS, INC. and PENINSULA LABORATORIES  
3 INTERNATIONAL, LLC as follows:

4 **INTRODUCTION**

5 1. This is an action for patent infringement brought by DRG  
6 INTERNATIONAL, INC. (hereinafter “DRG”), a New Jersey corporation with its  
7 principal place of business at 841 Mountain Avenue, Springfield, New Jersey  
8 07081, and which is the exclusive owner of United States patents covering methods  
9 and kits for the detection of hepcidin in humans, against Bachem Americas, Inc.  
10 (hereinafter “Bachem”) and Peninsula Laboratories International, Inc. (“Peninsula”)  
11 (collectively, “Defendants”) for infringement, contributory infringement, and  
12 inducement of infringement of those patents. DRG, by its attorneys, for its  
13 Complaint against Defendants alleges that:

14 **THE PARTIES**

15 2. Plaintiff DRG is a New Jersey corporation with its principal place of  
16 business at 841 Mountain Avenue, Springfield, New Jersey.

17 3. On information and belief, defendant Bachem is a California  
18 corporation with its principal place of business at 3132 Kishiwa Street, Torrance,  
19 California.

20 4. On information and belief, defendant Peninsula is a California  
21 corporation with its principal place of business at 305 Old Country Road, San  
22 Carlos, California.

23 **JURISDICTION AND VENUE**

24 5. This cause of action for patent infringement arises under the patent  
25 laws of the United States, Title 35, United States Code.

26 6. This Court has subject matter jurisdiction over this action pursuant to 28  
27 U.S.C. §§ 1331 and 1338(a), because this case involves patent infringement and arises  
28 under the laws of the United States, 15 U.S.C. § 1051, *et seq.*

7. This Court has personal jurisdiction over Bachem and Peninsula because Bachem and Peninsula have each committed acts of infringement within this District, Bachem resides in this District, Bachem and Peninsula conduct business in this District and Peninsula operates a website allowing California residents to directly purchase infringing products by selling antibodies and kits for the detection of hepcidin in humans.

8. Venue is proper in this District under 28 U.S.C. §§ 1391(b) and (c) and § 1400(b).

## BACKGROUND

9. DRG manufactures and markets kits for the detection of hepcidin in humans.

10. On January 22, 2008, the U.S. Patent and Trademark Office issued U.S. Patent No. 7,320,894, titled “Diagnostic Method for Diseases by Screening for Hepcidin in Human or Animal Tissues, Blood or Body Fluids and Therapeutic Uses Therefor” (“the ’894 patent”). A true and correct copy of the ’894 patent is attached hereto as Exhibit A.

11. DRG is the assignee of the '894 patent.

12. The '894 patent covers, among other things, a kit for detecting a disease condition characterized by non-physiological levels of hepcidin.

13. On August 12, 2008, the U.S. Patent and Trademark Office issued U.S. Patent No. 7,411,048, titled “Diagnostic Method for Diseases by Screening for Hepcidin in Human or Animal Tissues, Blood or Body Fluids and Therapeutic Uses Therefor” (“the ’048 patent”). A true and correct copy of the ’048 patent is attached hereto as Exhibit B.

14. DRG is the assignee of the '048 patent.

15. The '048 patent covers, among other things, a kit for detecting a disease condition characterized by non-physiological levels of hepcidin.

1           16.     On January 19, 2010, the U.S. Patent and Trademark Office issued  
2 U.S. Patent No. 7,649,081, titled “Diagnostic Method for Diseases by Screening for  
3 Hepcidin in Human or Animal Tissues, Blood or Body Fluids and Therapeutic Uses  
4 Therefor” (“the ’081 patent”). A true and correct copy of the ’081 patent is attached  
5 hereto as Exhibit C.

6           17.     DRG is the assignee of the ’081 patent.

7           18.     The ’081 patent covers, among other things, a kit for detecting a level of  
8 a hepcidin precursor.

9           19.     On August 16, 2011, the U.S. Patent and Trademark Office issued U.S.  
10 Patent No. 7,998,691, titled “Diagnostic Method for Diseases by Screening for  
11 Hepcidin in Human or Animal Tissues, Blood or Body Fluids and Therapeutic Uses  
12 Therefor” (“the ’691 patent”). A true and correct copy of the ’691 patent is attached  
13 hereto as Exhibit D.

14          20.     DRG is the assignee of the ’691 patent.

15          21.     The ’691 patent covers, among other things, a method for diagnosing  
16 hereditary hemochromatosis or chronic renal insufficiency.

17          22.     On August 23, 2011, the U.S. Patent and Trademark Office issued U.S.  
18 Patent No. 8,003,338, titled “Diagnostic Method for Diseases by Screening for  
19 Hepcidin in Human or Animal Tissues, Blood or Body Fluids and Therapeutic Uses  
20 Therefor” (“the ’338 patent”). A true and correct copy of the ’338 patent is attached  
21 hereto as Exhibit E.

22          23.     DRG is the assignee of the ’338 patent.

23          24.     The ’338 patent covers, among other things, a method of detecting a  
24 level of a hepcidin precursor in a sample from a patient.

25          25.     On September 13, 2011, the U.S. Patent and Trademark Office issued  
26 U.S. Patent No. 8,017,737, titled “Diagnostic Method for Diseases by Screening for  
27 Hepcidin in Human or Animal Tissues, Blood or Body Fluids; Monoclonal  
28

1 Antibodies Specific to Human Hepcidin and Associated Uses Thereof” (“the ’737  
2 patent”). A true and correct copy of the ’737 patent is attached hereto as Exhibit F.

3 26. DRG is the assignee of the ’737 patent.

4 27. The ’737 patent covers, among other things, an isolated antibody that  
5 specifically binds to the amino acid sequence of hepcidin peptides.

6 28. On November 6, 2012, the U.S. Patent and Trademark Office issued  
7 U.S. Patent No. 8,304,197, titled “Diagnostic Method for Diseases by Screening for  
8 Hepcidin in Human or Animal Tissues, Blood or Body Fluids and Therapeutic Uses  
9 Therefor” (“the ’197 patent”). A true and correct copy of the ’197 patent is attached  
10 hereto as Exhibit G.

11 29. DRG is the assignee of the ’197 patent.

12 30. The ’197 patent covers, among other things, a method of detecting a  
13 level of a hepcidin precursor in a sample from a patient.

14 31. On information and belief, Bachem makes and sells to Peninsula in the  
15 United States, among other things, the hepcidin peptide intended for use in the  
16 Peninsula kits for the detection of hepcidin in humans.

17 32. On its website, Bachem offers for sale Hepcidin-25 (human). A true and  
18 correct copy of Bachem’s Products webpage is attached hereto as Exhibit H.

19 33. On information and belief, Bachem previously made, used, sold and  
20 offered for sale in the United States, among other things, antibodies and kits for the  
21 detection of hepcidin in humans.

22 34. On information and belief, Peninsula makes, uses, sells and offers for  
23 sale in the United States, among other things, antibodies and kits for the detection  
24 of hepcidin in humans.

25 35. On its website, Peninsula offers for sale “Hepcidin-25 (human) -  
26 Purified Antiserum; Hepcidin-25 (human) – RIA Kit; Hepcidin-25 (human) – EIA  
27 Kit; Peptide Radioimmunoassay (RIA) Protocols; and Peptide Enzyme Immunoassay  
28

1 (EIA) protocols.” A true and correct copy of Peninsula’s Products webpage is  
2 attached hereto as Exhibit I.

3 36. On information and belief, Peninsula has used, sold, and/or offered for  
4 sale and continues to use, sell, and/or offer for sale products that infringe,  
5 contribute to the infringement, and/or induce the infringement of the DRG patents.

6 **COUNT I**

7 **(Direct Infringement of the ’894 Patent)**

8 37. DRG incorporates by reference the factual allegations contained in  
9 paragraphs 1 through 36 of this complaint, as if fully set forth herein.

10 38. On information and belief, Defendants have directly infringed and are  
11 continuing to directly infringe the ’894 patent by manufacturing, using, selling,  
12 and/or offering for sale antibodies and kits for the detection of hepcidin in humans  
13 (products).

14 39. A true and correct copy of Peninsula’s website dated June 29, 2015  
15 evidencing Peninsula’s offering for sale antibodies and kits for the detection of  
16 hepcidin in humans is attached hereto as Exhibit I.

17 40. On information and belief, Defendants have committed the  
18 aforementioned acts of infringement with full knowledge of the ’894 patent and  
19 DRG’s rights therein because, among other things, DRG has marked its own kits for  
20 the detection of hepcidin in humans identifying the ’894 patent. A true and correct  
21 copy of the product marking is attached as Exhibit J.

22 41. On information and belief, Defendants have committed the  
23 aforementioned acts of infringement with full knowledge of the ’894 patent and  
24 DRG’s rights therein because, among other things, DRG has sent a letter to  
25 Peninsula identifying the ’894 patent. A true and correct copy of the DRG letter is  
26 enclosed as Exhibit K.

27 42. All of the aforementioned infringing acts by Defendants are without  
28 the permission, license, or consent of DRG.

43. All of the aforementioned infringing acts by Defendants have been, and continue to be, willful and deliberate, and DRG believes that such acts will continue in the future unless Defendants are enjoined by this Court.

44. By reason of Defendants' acts of infringement, they have been unjustly enriched.

45. By reason of Defendants' acts of infringement, DRG has suffered and will continue to suffer irreparable harm and damages, including, but not limited to, lost sales and diminution of the value of the '894 patent, in an amount to be determined.

46. As a result of the continuing harm to DRG and the diminution of the value of the '894 patent, DRG has no remedy at law.

## COUNT II

**(Induced Infringement of the '894 Patent)**

47. DRG incorporates by reference the factual allegations contained in paragraphs 1 through 46 of this complaint, as if fully set forth herein.

48. On information and belief, Defendants have induced the infringement and are continuing to induce the infringement of the '894 patent by manufacturing, using, selling, and/or offering for sale antibodies and kits for the detection of hepcidin in humans (products).

49. On information and belief, Defendants intend to cause others to infringe the '894 patent by supplying their customers with infringing products with the knowledge that their customers' actions constitute direct infringement.

50. On information and belief, Defendants' customers are directly infringing and continue to directly infringe the '894 patent by manufacturing, using, selling, and/or offering for sale antibodies and kits for the detection of hepcidin in humans (products) supplied by Defendants.

51. On information and belief, Defendants have committed the  
aforementioned acts of infringement with full knowledge of the '894 patent and



1 DRG's rights therein because, among other things, DRG has marked its own kits for  
2 the detection of hepcidin in humans identifying the '894 patent. A true and correct  
3 copy of the product marking is enclosed as Exhibit J.

4 52. On information and belief, Defendants have committed the  
5 aforementioned acts of infringement with full knowledge of the '894 patent and  
6 DRG's rights therein because, among other things, DRG has sent a letter to  
7 Peninsula identifying the '894 patent. A true and correct copy of the DRG letter is  
8 attached as Exhibit K.

9 53. All of the aforementioned infringing acts by Defendants and/or others  
10 are without the permission, license, or consent of DRG.

11 54. All of the aforementioned infringing acts by Defendants have been,  
12 and continue to be, willful and deliberate, and DRG believes that such acts will  
13 continue in the future unless Defendants are enjoined by this Court.

14 55. By reason of Defendants' acts of induced infringement, they have been  
15 unjustly enriched.

16 56. By reason of Defendants' acts of induced infringement, DRG has  
17 suffered and will continue to suffer irreparable harm and damages, including, but  
18 not limited to, lost sales and diminution of the value of the '894 patent, in an  
19 amount to be determined.

20 57. As a result of the continuing harm to DRG and the diminution of the  
21 value of the '894 patent, DRG has no remedy at law.

22 **COUNT III**

23 **(Contributory Infringement of the '894 Patent)**

24 58. DRG incorporates by reference the factual allegations contained in  
25 paragraphs 1 through 57 of this complaint, as if fully set forth herein.

26 59. On information and belief, Defendants have contributed to the  
27 infringement and are continuing to contribute to the infringement of the '894 patent  
28



1 by manufacturing, using, importing, selling, and/or offering for sale antibodies and  
2 kits for the detection of hepcidin in humans (products).

3 60. On information and belief, Defendants' customers are directly  
4 infringing and continue to directly infringe the '894 patent by manufacturing, using,  
5 importing, selling, and/or offering for sale antibodies and kits for the detection of  
6 hepcidin in humans (products).

7 61. On information and belief, Defendants' antibodies and kits for the  
8 detection of hepcidin in humans (products) are a material part of the '894 patent,  
9 and are known by Defendant to be especially made or especially adapted for use in  
10 infringement of the '894 patent.

11 62. On information and belief, Defendants' antibodies and kits for the  
12 detection of hepcidin in humans (products) have no other substantial non-infringing  
13 uses.

14 63. On information and belief, Defendants have committed the  
15 aforementioned acts of infringement with full knowledge of the '894 patent and  
16 DRG's rights therein because, among other things, DRG has marked its own kits for  
17 the detection of hepcidin in humans identifying the '894 patent. A true and correct  
18 copy of the product marking is enclosed as Exhibit J.

19 64. On information and belief, Defendants have committed the  
20 aforementioned acts of infringement with full knowledge of the '894 patent and  
21 DRG's rights therein because, among other things, DRG has sent a letter to  
22 Peninsula identifying the '894 patent. A true and correct copy of the DRG letter is  
23 attached as Exhibit K.

24 65. All of the aforementioned infringing acts by Defendants and/or others  
25 are without the permission, license, or consent of DRG.

26 66. All of the aforementioned infringing acts by Defendants have been,  
27 and continues to be, willful and deliberate, and DRG believes that such acts will  
28 continue in the future unless Defendant is enjoined by this Court.

68. By reason of Defendants' acts of contributory infringement, DRG has suffered and will continue to suffer irreparable harm and damages, including, but not limited to, lost sales and diminution of the value of the '894 patent, in an amount to be determined.

69. As a result of the continuing harm to DRG and the diminution of the value of the '894 patent, DRG has no remedy at law.

### COUNT IV

**(Direct Infringement of the '048 Patent)**

70. DRG incorporates by reference the factual allegations contained in paragraphs 1 through 69 of this complaint, as if fully set forth herein.

71. On information and belief, Defendants have directly infringed and are continuing to directly infringe the '048 patent by manufacturing, using, selling, and/or offering for sale antibodies and kits for the detection of hepcidin in humans (products).

72. A true and correct copy of Peninsula's website dated June 29, 2015 evidencing Peninsula's offering for sale antibodies and kits for the detection of hepcidin in humans is attached hereto as Exhibit I.

73. On information and belief, Defendants have committed the aforementioned acts of infringement with full knowledge of the '048 patent and DRG's rights therein because, among other things, DRG has marked its own kits for the detection of hepcidin in humans identifying the '048 patent. A true and correct copy of the product marking is attached as Exhibit J.

74. On information and belief, Defendants have committed the aforementioned acts of infringement with full knowledge of the '048 patent and DRG's rights therein because, among other things, DRG has sent a letter to

1 Peninsula identifying the '048 patent. A true and correct copy of the DRG letter is  
2 attached as Exhibit K.

3 75. All of the aforementioned infringing acts by Defendants are without  
4 the permission, license, or consent of DRG.

5 76. All of the aforementioned infringing acts by Defendants have been,  
6 and continue to be, willful and deliberate, and DRG believes that such acts will  
7 continue in the future unless Defendants are enjoined by this Court.

8 77. By reason of Defendants' acts of infringement, they have been unjustly  
9 enriched.

10 78. By reason of Defendants' acts of infringement, DRG has suffered and  
11 will continue to suffer irreparable harm and damages, including, but not limited to,  
12 lost sales and diminution of the value of the '048 patent, in an amount to be  
13 determined.

14 79. As a result of the continuing harm to DRG and the diminution of the  
15 value of the '048 patent, DRG has no remedy at law.

16 **COUNT V**

17 **(Induced Infringement of the '048 Patent)**

18 80. DRG incorporates by reference the factual allegations contained in  
19 paragraphs 1 through 79 of this complaint, as if fully set forth herein.

20 81. On information and belief, Defendants have induced the infringement  
21 and are continuing to induce the infringement of the '048 patent by manufacturing,  
22 using, selling, and/or offering for sale antibodies and kits for the detection of  
23 hepcidin in humans (products).

24 82. On information and belief, Defendants intend to cause others to  
25 infringe the '048 patent by supplying their customers with infringing products with  
26 the knowledge that their customers' actions constitute direct infringement.

27 83. On information and belief, Defendants' customers are directly  
28 infringing and continue to directly infringe the '048 patent by manufacturing, using,

1 selling, and/or offering for sale antibodies and kits for the detection of hepcidin in  
2 humans (products) supplied by Defendants.

3 84. On information and belief, Defendants have committed the  
4 aforementioned acts of infringement with full knowledge of the '048 patent and  
5 DRG's rights therein because, among other things, DRG has marked its own kits for  
6 the detection of hepcidin in humans identifying the '048 patent. A true and correct  
7 copy of the product marking is enclosed as Exhibit J.

8 85. On information and belief, Defendants have committed the  
9 aforementioned acts of infringement with full knowledge of the '048 patent and  
10 DRG's rights therein because, among other things, DRG has sent a letter to  
11 Peninsula identifying the '048 patent. A true and correct copy of the DRG letter is  
12 attached as Exhibit K.

13 86. All of the aforementioned infringing acts by Defendants and/or others  
14 are without the permission, license, or consent of DRG.

15 87. All of the aforementioned infringing acts by Defendants have been,  
16 and continue to be, willful and deliberate, and DRG believes that such acts will  
17 continue in the future unless Defendants are enjoined by this Court.

18 88. By reason of Defendants' acts of induced infringement, they have been  
19 unjustly enriched.

20 89. By reason of Defendants' acts of induced infringement, DRG has  
21 suffered and will continue to suffer irreparable harm and damages, including, but  
22 not limited to, lost sales and diminution of the value of the '048 patent, in an  
23 amount to be determined.

24 90. As a result of the continuing harm to DRG and the diminution of the  
25 value of the '048 patent, DRG has no remedy at law.

26 **COUNT VI**

27 **(Contributory Infringement of the '048 Patent)**

1           91.     DRG incorporates by reference the factual allegations contained in  
2 paragraphs 1 through 90 of this complaint, as if fully set forth herein.

3           92.     On information and belief, Defendants have contributed to the  
4 infringement and are continuing to contribute to the infringement of the '048 patent  
5 by manufacturing, using, importing, selling, and/or offering for sale antibodies and  
6 kits for the detection of hepcidin in humans (products).

7           93.     On information and belief, Defendants' customers are directly  
8 infringing and continue to directly infringe the '048 patent by manufacturing, using,  
9 importing, selling, and/or offering for sale antibodies and kits for the detection of  
10 hepcidin in humans (products).

11           94.     On information and belief, Defendants' antibodies and kits for the  
12 detection of hepcidin in humans (products) are a material part of the '048 patent,  
13 and are known by Defendant to be especially made or especially adapted for use in  
14 infringement of the '048 patent.

15           95.     On information and belief, Defendants' antibodies and kits for the  
16 detection of hepcidin in humans (products) have no other substantial non-infringing  
17 uses.

18           96.     On information and belief, Defendants have committed the  
19 aforementioned acts of infringement with full knowledge of the '048 patent and  
20 DRG's rights therein because, among other things, DRG has marked its own kits for  
21 the detection of hepcidin in humans identifying the '048 patent. A true and correct  
22 copy of the product marking is enclosed as Exhibit J.

23           97.     On information and belief, Defendants have committed the  
24 aforementioned acts of infringement with full knowledge of the '048 patent and  
25 DRG's rights therein because, among other things, DRG has sent a letter to  
26 Peninsula identifying the '048 patent. A true and correct copy of the DRG letter is  
27 attached as Exhibit K.  
28

99. All of the aforementioned infringing acts by Defendants have been, and continues to be, willful and deliberate, and DRG believes that such acts will continue in the future unless Defendant is enjoined by this Court.

100. By reason of Defendants' acts of contributory infringement, they have been unjustly enriched.

101. By reason of Defendants' acts of contributory infringement, DRG has suffered and will continue to suffer irreparable harm and damages, including, but not limited to, lost sales and diminution of the value of the '048 patent, in an amount to be determined.

102. As a result of the continuing harm to DRG and the diminution of the value of the '048 patent, DRG has no remedy at law.

## COUNT VII

**(Direct Infringement of the '081 Patent)**

103. DRG incorporates by reference the factual allegations contained in paragraphs 1 through 102 of this complaint, as if fully set forth herein.

104. On information and belief, Defendants have directly infringed and are continuing to directly infringe the '081 patent by manufacturing, using, selling, and/or offering for sale antibodies and kits for the detection of hepcidin in humans (products).

105. A true and correct copy of Peninsula's website dated June 29, 2015 evidencing Peninsula's offering for sale antibodies and kits for the detection of hepcidin in humans is attached hereto as Exhibit I.

106. On information and belief, Defendants have committed the  
aforementioned acts of infringement with full knowledge of the '081 patent and  
DRG's rights therein because, among other things, DRG has marked its own kits for

1 the detection of hepcidin in humans identifying the '081 patent. A true and correct  
2 copy of the product marking is attached as Exhibit J.

3 107. On information and belief, Defendants have committed the  
4 aforementioned acts of infringement with full knowledge of the '081 patent and  
5 DRG's rights therein because, among other things, DRG has sent a letter to  
6 Peninsula identifying the '081 patent. A true and correct copy of the DRG letter is  
7 attached as Exhibit K.

8 108. All of the aforementioned infringing acts by Defendants are without  
9 the permission, license, or consent of DRG.

10 109. All of the aforementioned infringing acts by Defendants have been,  
11 and continue to be, willful and deliberate, and DRG believes that such acts will  
12 continue in the future unless Defendants are enjoined by this Court.

13 110. By reason of Defendants' acts of infringement, they have been unjustly  
14 enriched.

15 111. By reason of Defendants' acts of infringement, DRG has suffered and  
16 will continue to suffer irreparable harm and damages, including, but not limited to,  
17 lost sales and diminution of the value of the '081 patent, in an amount to be  
18 determined.

19 112. As a result of the continuing harm to DRG and the diminution of the  
20 value of the '081 patent, DRG has no remedy at law.

### 21 **COUNT VIII**

#### 22 **(Induced Infringement of the '081 Patent)**

23 113. DRG incorporates by reference the factual allegations contained in  
24 paragraphs 1 through 112 of this complaint, as if fully set forth herein.

25 114. On information and belief, Defendants have induced the infringement  
26 and are continuing to induce the infringement of the '081 patent by manufacturing,  
27 using, selling, and/or offering for sale antibodies and kits for the detection of  
28 hepcidin in humans (products).



1           115. On information and belief, Defendants intend to cause others to  
2 infringe the '081 patent by supplying their customers with infringing products with  
3 the knowledge that their customers' actions constitute direct infringement.

4           116. On information and belief, Defendants' customers are directly  
5 infringing and continue to directly infringe the '081 patent by manufacturing, using,  
6 selling, and/or offering for sale antibodies and kits for the detection of hepcidin in  
7 humans (products) supplied by Defendants.

8           117. On information and belief, Defendants have committed the  
9 aforementioned acts of infringement with full knowledge of the '081 patent and  
10 DRG's rights therein because, among other things, DRG has marked its own kits for  
11 the detection of hepcidin in humans identifying the '081 patent. A true and correct  
12 copy of the product marking is enclosed as Exhibit J.

13           118. On information and belief, Defendants have committed the  
14 aforementioned acts of infringement with full knowledge of the '081 patent and  
15 DRG's rights therein because, among other things, DRG has sent a letter to  
16 Peninsula identifying the '081 patent. A true and correct copy of the DRG letter is  
17 attached as Exhibit K.

18           119. All of the aforementioned infringing acts by Defendants and/or others  
19 are without the permission, license, or consent of DRG.

20           120. All of the aforementioned infringing acts by Defendants have been, and  
21 continue to be, willful and deliberate, and DRG believes that such acts will continue  
22 in the future unless Defendants are enjoined by this Court.

23           121. By reason of Defendants' acts of induced infringement, they have been  
24 unjustly enriched.

25           122. By reason of Defendants' acts of induced infringement, DRG has  
26 suffered and will continue to suffer irreparable harm and damages, including, but not  
27 limited to, lost sales and diminution of the value of the '081 patent, in an amount to  
28 be determined.

123. As a result of the continuing harm to DRG and the diminution of the value of the '081 patent, DRG has no remedy at law.

**(Contributory Infringement of the '081 Patent)**

125. On information and belief, Defendants have contributed to the infringement and are continuing to contribute to the infringement of the '081 patent by manufacturing, using, importing, selling, and/or offering for sale antibodies and kits for the detection of hepcidin in humans (products).

127. On information and belief, Defendants' antibodies and kits for the detection of hepcidin in humans (products) are a material part of the '081 patent, and are known by Defendant to be especially made or especially adapted for use in infringement of the '048 patent.

129. On information and belief, Defendants have committed the aforementioned acts of infringement with full knowledge of the '081 patent and DRG's rights therein because, among other things, DRG has marked its own kits for the detection of hepcidin in humans identifying the '081 patent. A true and correct copy of the product marking is enclosed as Exhibit J.

1 DRG's rights therein because, among other things, DRG has sent a letter to  
 2 Peninsula identifying the '081 patent. A true and correct copy of the DRG letter is  
 3 attached as Exhibit K.

4 131. All of the aforementioned infringing acts by Defendants and/or others  
 5 are without the permission, license, or consent of DRG.

6 132. All of the aforementioned infringing acts by Defendants have been,  
 7 and continues to be, willful and deliberate, and DRG believes that such acts will  
 8 continue in the future unless Defendant is enjoined by this Court.

9 133. By reason of Defendants' acts of contributory infringement, they have  
 10 been unjustly enriched.

11 134. By reason of Defendants' acts of contributory infringement, DRG has  
 12 suffered and will continue to suffer irreparable harm and damages, including, but  
 13 not limited to, lost sales and diminution of the value of the '081 patent, in an amount  
 14 to be determined.

15 135. As a result of the continuing harm to DRG and the diminution of the  
 16 value of the '081 patent, DRG has no remedy at law.

### 17 **COUNT X**

#### 18 **(Direct Infringement of the '691 Patent)**

19 136. DRG incorporates by reference the factual allegations contained in  
 20 paragraphs 1 through 135 of this complaint, as if fully set forth herein.

21 137. On information and belief, Defendants have directly infringed and are  
 22 continuing to directly infringe the '691 patent by manufacturing, using, selling,  
 23 and/or offering for sale antibodies and kits for the detection of hepcidin in humans  
 24 (products).

25 138. A true and correct copy of Peninsula's website dated June 29, 2015  
 26 evidencing Peninsula's offering for sale antibodies and kits for the detection of  
 27 hepcidin in humans is attached hereto as Exhibit I.

140. On information and belief, Defendants have committed the aforementioned acts of infringement with full knowledge of the '691 patent and DRG's rights therein because, among other things, DRG has sent a letter to Peninsula identifying the '691 patent. A true and correct copy of the DRG letter is attached as Exhibit K.

142. All of the aforementioned infringing acts by Defendants have been, and continue to be, willful and deliberate, and DRG believes that such acts will continue in the future unless Defendants are enjoined by this Court.

144. By reason of Defendants' acts of infringement, DRG has suffered and will continue to suffer irreparable harm and damages, including, but not limited to, lost sales and diminution of the value of the '691 patent, in an amount to be determined.

**COUNT XI**

146. DRG incorporates by reference the factual allegations contained in paragraphs 1 through 145 of this complaint, as if fully set forth herein.

1           147. On information and belief, Defendants have induced the infringement  
2 and are continuing to induce the infringement of the '691 patent by manufacturing,  
3 using, selling, and/or offering for sale antibodies and kits for the detection of  
4 hepcidin in humans (products).

5           148. On information and belief, Defendants intend to cause others to  
6 infringe the '048 patent by supplying their customers with infringing products with  
7 the knowledge that their customers' actions constitute direct infringement.

8           149. On information and belief, Defendants' customers are directly  
9 infringing and continue to directly infringe the '691 patent by manufacturing, using,  
10 selling, and/or offering for sale antibodies and kits for the detection of hepcidin in  
11 humans (products) supplied by Defendants.

12           150. On information and belief, Defendants have committed the  
13 aforementioned acts of infringement with full knowledge of the '691 patent and  
14 DRG's rights therein because, among other things, DRG has marked its own kits for  
15 the detection of hepcidin in humans identifying the '691 patent. A true and correct  
16 copy of the product marking is enclosed as Exhibit J.

17           151. On information and belief, Defendants have committed the  
18 aforementioned acts of infringement with full knowledge of the '691 patent and  
19 DRG's rights therein because, among other things, DRG has sent a letter to  
20 Peninsula identifying the '691 patent. A true and correct copy of the DRG letter is  
21 attached as Exhibit K.

22           152. All of the aforementioned infringing acts by Defendant and/or others  
23 are without the permission, license, or consent of DRG.

24           153. All of the aforementioned infringing acts by Defendants have been,  
25 and continue to be, willful and deliberate, and DRG believes that such acts will  
26 continue in the future unless Defendants are enjoined by this Court.

27           154. By reason of Defendants' acts of induced infringement, they have been  
28 unjustly enriched.

156. As a result of the continuing harm to DRG and the diminution of the value of the '691 patent, DRG has no remedy at law.

## COUNT XII

157. DRG incorporates by reference the factual allegations contained in paragraphs 1 through 156 of this complaint, as if fully set forth herein.

159. On information and belief, Defendants' customers are directly infringing and continue to directly infringe the '691 patent by manufacturing, using, importing, selling, and/or offering for sale antibodies and kits for the detection of hepcidin in humans (products).

161. On information and belief, Defendants' antibodies and kits for the detection of hepcidin in humans (products) have no other substantial non-infringing uses.

162. On information and belief, Defendants have committed the  
aforementioned acts of infringement with full knowledge of the '691 patent and  
DRG's rights therein because, among other things, DRG has marked its own kits for  
the detection of hepcidin in humans identifying the '691 patent. A true and correct  
copy of the product marking is enclosed as Exhibit J.

163. On information and belief, Defendants have committed the  
aforementioned acts of infringement with full knowledge of the '691 patent and  
DRG's rights therein because, among other things, DRG has sent a letter to  
Peninsula identifying the '691 patent. A true and correct copy of the DRG letter is  
attached as Exhibit K.

164. All of the aforementioned infringing acts by Defendants and/or others are without the permission, license, or consent of DRG.

165. All of the aforementioned infringing acts by Defendants have been, and continues to be, willful and deliberate, and DRG believes that such acts will continue in the future unless Defendant is enjoined by this Court.

166. By reason of Defendants' acts of contributory infringement, they have been unjustly enriched.

167. By reason of Defendants' acts of contributory infringement, DRG has suffered and will continue to suffer irreparable harm and damages, including, but not limited to, lost sales and diminution of the value of the '691 patent, in an amount to be determined.

168. As a result of the continuing harm to DRG and the diminution of the value of the '691 patent, DRG has no remedy at law.

**COUNT XIII**

**(Direct Infringement of the '338 Patent)**

169. DRG incorporates by reference the factual allegations contained in paragraphs 1 through 169 of this complaint, as if fully set forth herein.



1 170. On information and belief, Defendants have directly infringed and are  
2 continuing to directly infringe the '338 patent by manufacturing, using, selling,  
3 and/or offering for sale antibodies and kits for the detection of hepcidin in humans  
4 (products).

5 171. A true and correct copy of Peninsula's website dated June 29, 2015  
6 evidencing Peninsula's offering for sale antibodies and kits for the detection of  
7 hepcidin in humans is attached hereto as Exhibit I.

8 172. On information and belief, Defendants have committed the  
9 aforementioned acts of infringement with full knowledge of the '338 patent and  
10 DRG's rights therein because, among other things, DRG has marked its own kits for  
11 the detection of hepcidin in humans identifying the '338 patent. A true and correct  
12 copy of the product marking is attached as Exhibit J.

13 173. On information and belief, Defendants have committed the  
14 aforementioned acts of infringement with full knowledge of the '338 patent and  
15 DRG's rights therein because, among other things, DRG has sent a letter to  
16 Peninsula identifying the '338 patent. A true and correct copy of the DRG letter is  
17 attached as Exhibit K.

18 174. All of the aforementioned infringing acts by Defendants are without  
19 the permission, license, or consent of DRG.

20 175. All of the aforementioned infringing acts by Defendants have been,  
21 and continue to be, willful and deliberate, and DRG believes that such acts will  
22 continue in the future unless Defendants are enjoined by this Court.

23 176. By reason of Defendants' acts of infringement, they have been unjustly  
24 enriched.

25 177. By reason of Defendants' acts of infringement, DRG has suffered and  
26 will continue to suffer irreparable harm and damages, including, but not limited to,  
27 lost sales and diminution of the value of the '338 patent, in an amount to be  
28 determined.

1 178. As a result of the continuing harm to DRG and the diminution of the  
2 value of the '338 patent, DRG has no remedy at law.

3 **COUNT XIV**

4 **(Induced Infringement of the '338 Patent)**

5 179. DRG incorporates by reference the factual allegations contained in  
6 paragraphs 1 through 178 of this complaint, as if fully set forth herein.

7 180. On information and belief, Defendants have induced the infringement  
8 and are continuing to induce the infringement of the '338 patent by manufacturing,  
9 using, selling, and/or offering for sale antibodies and kits for the detection of  
10 hepcidin in humans (products).

11 181. On information and belief, Defendants intend to cause others to  
12 infringe the '338 patent by supplying their customers with infringing products with  
13 the knowledge that their customers' actions constitute direct infringement.

14 182. On information and belief, Defendants' customers are directly  
15 infringing and continue to directly infringe the '338 patent by manufacturing, using,  
16 selling, and/or offering for sale antibodies and kits for the detection of hepcidin in  
17 humans (products) supplied by Defendants.

18 183. On information and belief, Defendants have committed the  
19 aforementioned acts of infringement with full knowledge of the '338 patent and  
20 DRG's rights therein because, among other things, DRG has marked its own kits for  
21 the detection of hepcidin in humans identifying the '338 patent. A true and correct  
22 copy of the product marking is enclosed as Exhibit J.

23 184. On information and belief, Defendants have committed the  
24 aforementioned acts of infringement with full knowledge of the '338 patent and  
25 DRG's rights therein because, among other things, DRG has sent a letter to  
26 Peninsula identifying the '338 patent. A true and correct copy of the DRG letter is  
27 attached as Exhibit K.  
28

1 185. All of the aforementioned infringing acts by Defendants and/or others  
2 are without the permission, license, or consent of DRG.

3 186. All of the aforementioned infringing acts by Defendants have been,  
4 and continue to be, willful and deliberate, and DRG believes that such acts will  
5 continue in the future unless Defendants are enjoined by this Court.

6 187. By reason of Defendants' acts of induced infringement, they have been  
7 unjustly enriched.

8 188. By reason of Defendants' acts of induced infringement, DRG has  
9 suffered and will continue to suffer irreparable harm and damages, including, but not  
10 limited to, lost sales and diminution of the value of the '338 patent, in an amount to  
11 be determined.

12 189. As a result of the continuing harm to DRG and the diminution of the  
13 value of the '338 patent, DRG has no remedy at law.

14 **COUNT XV**

15 **(Contributory Infringement of the '338 Patent)**

16 190. DRG incorporates by reference the factual allegations contained in  
17 paragraphs 1 through 189 of this complaint, as if fully set forth herein.

18 191. On information and belief, Defendants have contributed to the  
19 infringement and are continuing to contribute to the infringement of the '338 patent  
20 by manufacturing, using, importing, selling, and/or offering for sale antibodies and  
21 kits for the detection of hepcidin in humans (products).

22 192. On information and belief, Defendants' customers are directly  
23 infringing and continue to directly infringe the '338 patent by manufacturing, using,  
24 importing, selling, and/or offering for sale antibodies and kits for the detection of  
25 hepcidin in humans (products).

26 193. On information and belief, Defendants' antibodies and kits for the  
27 detection of hepcidin in humans (products) are for use in practicing a process  
28 patented in the '338 patent. Further, Defendants' antibodies and kits for the

1 detection of hepcidin in humans (products) are a material part of the '338 patent,  
2 and are known by Defendant to be especially made or especially adapted for use in  
3 infringement of the '338 patent.

4 194. On information and belief, Defendants' antibodies and kits for the  
5 detection of hepcidin in humans (products) have no other substantial non-infringing  
6 uses.

7 195. On information and belief, Defendants have committed the  
8 aforementioned acts of infringement with full knowledge of the '338 patent and  
9 DRG's rights therein because, among other things, DRG has marked its own kits for  
10 the detection of hepcidin in humans identifying the '338 patent. A true and correct  
11 copy of the product marking is enclosed as Exhibit J.

12 196. On information and belief, Defendants have committed the  
13 aforementioned acts of infringement with full knowledge of the '338 patent and  
14 DRG's rights therein because, among other things, DRG has sent a letter to  
15 Peninsula identifying the '338 patent. A true and correct copy of the DRG letter is  
16 attached as Exhibit K.

17 197. All of the aforementioned infringing acts by Defendants and/or others  
18 are without the permission, license, or consent of DRG.

19 198. All of the aforementioned infringing acts by Defendants have been,  
20 and continues to be, willful and deliberate, and DRG believes that such acts will  
21 continue in the future unless Defendant is enjoined by this Court.

22 199. By reason of Defendants' acts of contributory infringement, they have  
23 been unjustly enriched.

24 200. By reason of Defendants' acts of contributory infringement, DRG has  
25 suffered and will continue to suffer irreparable harm and damages, including, but  
26 not limited to, lost sales and diminution of the value of the '338 patent, in an amount  
27 to be determined.  
28

201. As a result of the continuing harm to DRG and the diminution of the value of the '338 patent, DRG has no remedy at law.

**(Direct Infringement of the '737 Patent)**

203. On information and belief, Defendants have directly infringed and are continuing to directly infringe the '737 patent by manufacturing, using, selling, and/or offering for sale antibodies and kits for the detection of hepcidin in humans (products).

205. On information and belief, Defendants have committed the aforementioned acts of infringement with full knowledge of the '737 patent and DRG's rights therein because, among other things, DRG has marked its own kits for the detection of hepcidin in humans identifying the '737 patent. A true and correct copy of the product marking is attached as Exhibit J.

207. All of the aforementioned infringing acts by Defendants are without the permission, license, or consent of DRG.

209. By reason of Defendants' acts of infringement, they have been unjustly enriched.

210. By reason of Defendants' acts of infringement, DRG has suffered and will continue to suffer irreparable harm and damages, including, but not limited to, lost sales and diminution of the value of the '737 patent, in an amount to be determined.

211. As a result of the continuing harm to DRG and the diminution of the value of the '737 patent, DRG has no remedy at law.

**COUNT XVII**

**(Induced Infringement of the '737 Patent)**

212. DRG incorporates by reference the factual allegations contained in paragraphs 1 through 211 of this complaint, as if fully set forth herein.

213. On information and belief, Defendants have induced the infringement and are continuing to induce the infringement of the '737 patent by manufacturing, using, selling, and/or offering for sale antibodies and kits for the detection of hepcidin in humans (products).

214. On information and belief, Defendants intend to cause others to infringe the '737 patent by supplying their customers with infringing products with the knowledge that their customers' actions constitute direct infringement.

215. On information and belief, Defendants' customers are directly infringing and continue to directly infringe the '737 patent by manufacturing, using, selling, and/or offering for sale antibodies and kits for the detection of hepcidin in humans (products) supplied by Defendants.

216. On information and belief, Defendants have committed the aforementioned acts of infringement with full knowledge of the '737 patent and DRG's rights therein because, among other things, DRG has marked its own kits for the detection of hepcidin in humans identifying the '737 patent. A true and correct copy of the product marking is enclosed as Exhibit J.

217. On information and belief, Defendants have committed the aforementioned acts of infringement with full knowledge of the '737 patent and DRG's rights therein because, among other things, DRG has sent a letter to Peninsula identifying the '737 patent. A true and correct copy of the DRG letter is attached as Exhibit K.

218. All of the aforementioned infringing acts by Defendants and/or others are without the permission, license, or consent of DRG.

219. All of the aforementioned infringing acts by Defendants have been, and continue to be, willful and deliberate, and DRG believes that such acts will continue in the future unless Defendants are enjoined by this Court.

220. By reason of Defendants' acts of induced infringement, they have been unjustly enriched.

221. By reason of Defendants' acts of induced infringement, DRG has suffered and will continue to suffer irreparable harm and damages, including, but not limited to, lost sales and diminution of the value of the '737 patent, in an amount to be determined.

222. As a result of the continuing harm to DRG and the diminution of the value of the '737 patent, DRG has no remedy at law.

### COUNT XVIII

**(Contributory Infringement of the '737 Patent)**

223. DRG incorporates by reference the factual allegations contained in paragraphs 1 through 222 of this complaint, as if fully set forth herein.

224. On information and belief, Defendants have contributed to the infringement and are continuing to contribute to the infringement of the '737 patent by manufacturing, using, importing, selling, and/or offering for sale antibodies and kits for the detection of hepcidin in humans (products).

225. On information and belief, Defendants' customers are directly infringing and continue to directly infringe the '737 patent by manufacturing, using,



1 importing, selling, and/or offering for sale antibodies and kits for the detection of  
2 hepcidin in humans (products).

3 226. On information and belief, Defendants' antibodies and kits for the  
4 detection of hepcidin in humans (products) are a material part of the '737 patent,  
5 and are known by Defendant to be especially made or especially adapted for use in  
6 infringement of the '737 patent.

7 227. On information and belief, Defendants' antibodies and kits for the  
8 detection of hepcidin in humans (products) have no other substantial non-infringing  
9 uses.

10 228. On information and belief, Defendants have committed the  
11 aforementioned acts of infringement with full knowledge of the '737 patent and  
12 DRG's rights therein because, among other things, DRG has marked its own kits for  
13 the detection of hepcidin in humans identifying the '737 patent. A true and correct  
14 copy of the product marking is enclosed as Exhibit J.

15 229. On information and belief, Defendants have committed the  
16 aforementioned acts of infringement with full knowledge of the '737 patent and  
17 DRG's rights therein because, among other things, DRG has sent a letter to  
18 Peninsula identifying the '737 patent. A true and correct copy of the DRG letter is  
19 attached as Exhibit K.

20 230. All of the aforementioned infringing acts by Defendants and/or others  
21 are without the permission, license, or consent of DRG.

22 231. All of the aforementioned infringing acts by Defendants have been,  
23 and continues to be, willful and deliberate, and DRG believes that such acts will  
24 continue in the future unless Defendant is enjoined by this Court.

25 232. By reason of Defendants' acts of contributory infringement, they have  
26 been unjustly enriched.

27 233. By reason of Defendants' acts of contributory infringement, DRG has  
28 suffered and will continue to suffer irreparable harm and damages, including, but

1 not limited to, lost sales and diminution of the value of the '737 patent, in an amount  
2 to be determined.

3 234. As a result of the continuing harm to DRG and the diminution of the  
4 value of the '737 patent, DRG has no remedy at law.

5 **COUNT XIX**

6 **(Direct Infringement of the '197 Patent)**

7 235. DRG incorporates by reference the factual allegations contained in  
8 paragraphs 1 through 234 of this complaint, as if fully set forth herein.

9 236. On information and belief, Defendants have directly infringed and are  
10 continuing to directly infringe the '197 patent by manufacturing, using, selling,  
11 and/or offering for sale antibodies and kits for the detection of hepcidin in humans  
12 (products).

13 237. A true and correct copy of Peninsula's website dated June 29, 2015  
14 evidencing Peninsula's offering for sale antibodies and kits for the detection of  
15 hepcidin in humans is attached hereto as Exhibit I.

16 238. On information and belief, Defendants have committed the  
17 aforementioned acts of infringement with full knowledge of the '197 patent and  
18 DRG's rights therein because, among other things, DRG has marked its own kits for  
19 the detection of hepcidin in humans identifying the '197 patent. A true and correct  
20 copy of the product marking is attached as Exhibit J.

21 239. On information and belief, Defendants have committed the  
22 aforementioned acts of infringement with full knowledge of the '197 patent and  
23 DRG's rights therein because, among other things, DRG has sent a letter to  
24 Peninsula identifying the '197 patent. A true and correct copy of the DRG letter is  
25 attached as Exhibit K.

26 240. All of the aforementioned infringing acts by Defendants are without  
27 the permission, license, or consent of DRG.  
28

241. All of the aforementioned infringing acts by Defendants have been, and continue to be, willful and deliberate, and DRG believes that such acts will continue in the future unless Defendants are enjoined by this Court.

242. By reason of Defendants' acts of infringement, they have been unjustly enriched.

243. By reason of Defendants' acts of infringement, DRG has suffered and will continue to suffer irreparable harm and damages, including, but not limited to, lost sales and diminution of the value of the '197 patent, in an amount to be determined.

244. As a result of the continuing harm to DRG and the diminution of the value of the '197 patent, DRG has no remedy at law.

**COUNT XX**

**(Induced Infringement of the '197 Patent)**

245. DRG incorporates by reference the factual allegations contained in paragraphs 1 through 244 of this complaint, as if fully set forth herein.

246. On information and belief, Defendants have induced the infringement and are continuing to induce the infringement of the '197 patent by manufacturing, using, selling, and/or offering for sale antibodies and kits for the detection of hepcidin in humans (products).

247. On information and belief, Defendants intend to cause others to infringe the '197 patent by supplying their customers with infringing products with the knowledge that their customers' actions constitute direct infringement.

248. On information and belief, Defendants' customers are directly infringing and continue to directly infringe the '197 patent by manufacturing, using, selling, and/or offering for sale antibodies and kits for the detection of hepcidin in humans (products) supplied by Defendants.

249. On information and belief, Defendants have committed the  
aforementioned acts of infringement with full knowledge of the '197 patent and

1 DRG's rights therein because, among other things, DRG has marked its own kits for  
2 the detection of hepcidin in humans identifying the '197 patent. A true and correct  
3 copy of the product marking is enclosed as Exhibit J.

4 250. On information and belief, Defendants have committed the  
5 aforementioned acts of infringement with full knowledge of the '197 patent and  
6 DRG's rights therein because, among other things, DRG has sent a letter to  
7 Peninsula identifying the '197 patent. A true and correct copy of the DRG letter is  
8 attached as Exhibit K.

9 251. All of the aforementioned infringing acts by Defendants and/or others  
10 are without the permission, license, or consent of DRG.

11 252. All of the aforementioned infringing acts by Defendants have been,  
12 and continue to be, willful and deliberate, and DRG believes that such acts will  
13 continue in the future unless Defendants are enjoined by this Court.

14 253. By reason of Defendants' acts of induced infringement, they have been  
15 unjustly enriched.

16 254. By reason of Defendants' acts of induced infringement, DRG has  
17 suffered and will continue to suffer irreparable harm and damages, including, but not  
18 limited to, lost sales and diminution of the value of the '197 patent, in an amount to  
19 be determined.

20 255. As a result of the continuing harm to DRG and the diminution of the  
21 value of the '197 patent, DRG has no remedy at law.

## 22 **COUNT XXI**

### 23 **(Contributory Infringement of the '197 Patent)**

24 256. DRG incorporates by reference the factual allegations contained in  
25 paragraphs 1 through 255 of this complaint, as if fully set forth herein.

26 257. On information and belief, Defendants have contributed to the  
27 infringement and are continuing to contribute to the infringement of the '197 patent  
28

1 by manufacturing, using, importing, selling, and/or offering for sale antibodies and  
2 kits for the detection of hepcidin in humans (products).

3 258. On information and belief, Defendants' customers are directly  
4 infringing and continue to directly infringe the '197 patent by manufacturing, using,  
5 importing, selling, and/or offering for sale antibodies and kits for the detection of  
6 hepcidin in humans (products).

7 259. On information and belief, Defendants' antibodies and kits for the  
8 detection of hepcidin in humans (products) are for use in practicing a process  
9 patented in the '197 patent. Further, Defendants' antibodies and kits for the  
10 detection of hepcidin in humans (products) are a material part of the '197 patent,  
11 and are known by Defendant to be especially made or especially adapted for use in  
12 infringement of the '197 patent.

13 260. On information and belief, Defendants' antibodies and kits for the  
14 detection of hepcidin in humans (products) have no other substantial non-infringing  
15 uses.

16 261. On information and belief, Defendants have committed the  
17 aforementioned acts of infringement with full knowledge of the '197 patent and  
18 DRG's rights therein because, among other things, DRG has marked its own kits for  
19 the detection of hepcidin in humans identifying the '197 patent. A true and correct  
20 copy of the product marking is enclosed as Exhibit J.

21 262. On information and belief, Defendants have committed the  
22 aforementioned acts of infringement with full knowledge of the '197 patent and  
23 DRG's rights therein because, among other things, DRG has sent a letter to  
24 Peninsula identifying the '197 patent. A true and correct copy of the DRG letter is  
25 attached as Exhibit K.

26 263. All of the aforementioned infringing acts by Defendants and/or others  
27 are without the permission, license, or consent of DRG.  
28

264. All of the aforementioned infringing acts by Defendants have been, and continues to be, willful and deliberate, and DRG believes that such acts will continue in the future unless Defendant is enjoined by this Court.

265. By reason of Defendants' acts of contributory infringement, they have been unjustly enriched.

266. By reason of Defendants' acts of contributory infringement, DRG has suffered and will continue to suffer irreparable harm and damages, including, but not limited to, lost sales and diminution of the value of the '197 patent, in an amount to be determined.

267. As a result of the continuing harm to DRG and the diminution of the value of the '197 patent, DRG has no remedy at law.

**RELIEF SOUGHT:**

WHEREFORE, DRG respectfully requests that this Court:

(1) Rule that Defendants' antibodies and kits for the detection of hepcidin in humans (products) infringe, contribute to the infringement, and/or induce the infringement of the '894, '048, '081, '691, '338, '737 and '197 patents;

(2) Grant a preliminary and/or permanent injunction against the continued infringement, contributory infringement, and/or induced infringement of the '894, '048, '081, '691, '338, '737 and '197 patents by Defendants and each of their agents, servants, employees, attorneys, officers, and all others in privity and acting in concert with them;

(3) Order an accounting to determine and assess against Defendants an award to fully compensate DRG for damages arising out of Defendants' infringement, contributory infringement, and/or induced infringement of the '894, '048, '081, '691, '338, '737 and '197 patents;

(4) Order that this case be deemed exceptional under 35 U.S.C. § 285;

(5) Award treble damages against Defendants by reason of the willful and deliberate nature of their infringement;

1 (6) Award DRG its costs and reasonable attorneys' fees incurred in this  
2 action; and

3 (7) Grant DRG any such other, further, different, or additional relief as  
4 this Court deems just, equitable, and proper.

5 **DEMAND FOR JURY TRIAL**

6 DRG demands trial by jury on all issues triable to a jury.

7  
8 Dated: September 16, 2015

FOX ROTHSCHILD LLP

9  
10 By /s/ John Shaeffer

John Shaeffer

11 Jeffrey Grant

12 Lena N. Bacani

Attorneys for Plaintiff,

13 DRG INTERNATIONAL, INC.



**JURY DEMAND**

Plaintiff DRG INTERNATIONAL, INC. hereby demands a jury on all claims  
so triable.

Dated: September 16, 2015

FOX ROTHSCHILD LLP

By /s/ Lena N. Bacani

John Shaeffer

Lena N. Bacani

Jeffrey Grant

Attorneys for Plaintiff,  
DRG INTERNATIONAL, INC.